CagriSema vs Mazdutide
CagriSema and mazdutide differ in mechanism, trial maturity, and regulatory status. The cited studies do not establish a head-to-head efficacy ranking.
Last updated: September 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
CagriSema
Dossier overview
Mazdutide
Dossier overview
What the evidence actually compares
CagriSema is coadministered cagrilintide (an amylin analogue) and semaglutide (a GLP-1 agonist). It is a two-drug combination, not one new dual-agonist molecule. Mazdutide is one GLP-1/glucagon dual agonist.
The published phase 3 REDEFINE 1 trial randomized adults with overweight or obesity to the combination, its components or placebo and evaluated weight at 68 weeks. REIMAGINE trials study type 2 diabetes populations and different endpoints. These combination-specific results must not be imported into the monotherapy evidence for cagrilintide or semaglutide. REDEFINE 1, PMID 40544433 · REIMAGINE 2, PMID 42251859
Mazdutide is a GLP-1/glucagon receptor dual agonist. Its published GLORY-1 and GLORY-2 weight trials enrolled Chinese adults; GLORY-2 included some adults with type 2 diabetes, whereas the separate US phase 2 trial enrolled adults without it. The trials used different follow-up and analysis methods. GLORY-1 · GLORY-2 · US phase 2
Innovent reports Chinese NMPA approvals for specified adult weight-management and type 2 diabetes uses. The reviewed source is a sponsor exchange filing, not an independently retrieved Chinese label. No US FDA mazdutide approval was verified; an FDA letter identifies one US seller’s mazdutide products as unapproved new drugs.
| Evidence question | CagriSema | Mazdutide |
|---|---|---|
| Mechanism | CagriSema is coadministered cagrilintide (an amylin analogue) and semaglutide (a GLP-1 agonist). It is a two-drug combination, not one new dual-agonist molecule. Mazdutide is one GLP-1/glucagon dual agonist. | GLP-1/glucagon receptor dual agonist |
| Cited human weight evidence | Published combination phase 3 REDEFINE 1 study | Published GLORY phase 3 studies in Chinese adults; separate US phase 2 study |
| US status in reviewed sources | No FDA approval verified | No FDA approval verified |
| China status in reviewed sources | No jurisdiction-specific conclusion from cited CagriSema sources | Innovent reports specified adult weight and diabetes approvals |
What cannot be inferred
Mazdutide’s GLORY weight studies were conducted mainly in Chinese adults with different entry criteria and endpoint timing. REDEFINE 1 is not a direct mazdutide comparator, so a trial-percentage ranking would be unsupported.
Novo Nordisk reports filing a US obesity application for CagriSema in December 2025. Filing is not approval; no FDA approval decision was verified. No FDA mazdutide approval was verified. Innovent separately reports specified Chinese mazdutide approvals. The combination efficacy evidence above is REDEFINE 1; regulatory claims about mazdutide are supported by the linked sponsor filing and FDA letter. No combination-use claim follows from these separate studies.
This comparison is educational research context, not medical advice or a treatment protocol.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.